Cargando…
A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms
SARS-CoV-2, a new virus that appeared in Wuhan, China, in 2019 has approximately an 80% genomic match to the Severe Acute Respiratory Symptom (SARS) virus, which is known to come from a bat virus. Symptoms of Kawasaki disease in general and incomplete Kawasaki disease have been seen in a subset of p...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340733/ https://www.ncbi.nlm.nih.gov/pubmed/32638151 http://dx.doi.org/10.1007/s10787-020-00739-x |
_version_ | 1783555087048638464 |
---|---|
author | Roe, Kevin |
author_facet | Roe, Kevin |
author_sort | Roe, Kevin |
collection | PubMed |
description | SARS-CoV-2, a new virus that appeared in Wuhan, China, in 2019 has approximately an 80% genomic match to the Severe Acute Respiratory Symptom (SARS) virus, which is known to come from a bat virus. Symptoms of Kawasaki disease in general and incomplete Kawasaki disease have been seen in a subset of pediatric patients having a current or previous infection of SARS-CoV-2. A viral infection, such as a SARS-CoV-2 virus infection, could result in extensive antigen–antibody immune complexes that cannot be quickly cleared in a subset of patients and thus create a type III hypersensitivity immune reaction and cause Kawasaki disease or Kawasaki disease symptoms (also known as multisystem inflammatory syndrome) in a subset of patients. Extensive binding of antibodies to viral antigens can create antigen–antibody immune complexes, which, if not eliminated in certain individuals having dysfunctional complement systems, can start inflammatory type III hypersensitivity symptoms, including protease releases that can disrupt epithelium, mesothelium, and endothelium basement membranes, and induce pervasive inflammation throughout the body. This could continue after SARS-CoV-2 infections end if the first wave of protease attacks on basement membranes created new secondary autoantibodies and new uncleared antigen–antibody immune complexes. |
format | Online Article Text |
id | pubmed-7340733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73407332020-07-08 A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms Roe, Kevin Inflammopharmacology Short Communication SARS-CoV-2, a new virus that appeared in Wuhan, China, in 2019 has approximately an 80% genomic match to the Severe Acute Respiratory Symptom (SARS) virus, which is known to come from a bat virus. Symptoms of Kawasaki disease in general and incomplete Kawasaki disease have been seen in a subset of pediatric patients having a current or previous infection of SARS-CoV-2. A viral infection, such as a SARS-CoV-2 virus infection, could result in extensive antigen–antibody immune complexes that cannot be quickly cleared in a subset of patients and thus create a type III hypersensitivity immune reaction and cause Kawasaki disease or Kawasaki disease symptoms (also known as multisystem inflammatory syndrome) in a subset of patients. Extensive binding of antibodies to viral antigens can create antigen–antibody immune complexes, which, if not eliminated in certain individuals having dysfunctional complement systems, can start inflammatory type III hypersensitivity symptoms, including protease releases that can disrupt epithelium, mesothelium, and endothelium basement membranes, and induce pervasive inflammation throughout the body. This could continue after SARS-CoV-2 infections end if the first wave of protease attacks on basement membranes created new secondary autoantibodies and new uncleared antigen–antibody immune complexes. Springer International Publishing 2020-07-07 2020 /pmc/articles/PMC7340733/ /pubmed/32638151 http://dx.doi.org/10.1007/s10787-020-00739-x Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Short Communication Roe, Kevin A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title | A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title_full | A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title_fullStr | A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title_full_unstemmed | A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title_short | A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms |
title_sort | viral infection explanation for kawasaki disease in general and for covid-19 virus-related kawasaki disease symptoms |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340733/ https://www.ncbi.nlm.nih.gov/pubmed/32638151 http://dx.doi.org/10.1007/s10787-020-00739-x |
work_keys_str_mv | AT roekevin aviralinfectionexplanationforkawasakidiseaseingeneralandforcovid19virusrelatedkawasakidiseasesymptoms AT roekevin viralinfectionexplanationforkawasakidiseaseingeneralandforcovid19virusrelatedkawasakidiseasesymptoms |